Ivermectin to Treat Cancer

Evidence Review created on 08/02/2026 using AI4L / Opus 4.8

Also known as: Stromectol, Soolantra, Sklice, Mectizan, IVM

Motivation

Ivermectin (also sold as Stromectol) is an inexpensive, widely used medicine that has been given to hundreds of millions of people to treat parasitic infections such as river blindness and scabies. Over the past decade, laboratory studies have reported that the same drug can slow the growth of many kinds of cancer cells, which has led scientists and patients alike to ask whether an old, cheap, well-tolerated drug might be repurposed as a cancer treatment.

Interest grew from drug-screening projects that test existing medicines against tumor cells, and it intensified as the drug became a household name during the pandemic. Some clinics and online sellers now offer it for cancer, while cancer authorities caution that human proof is still missing and that misuse can cause harm.

This review examines what is actually known about ivermectin as a cancer treatment: how it is proposed to work, what laboratory and early human data show, the risks of taking it, and the ongoing trials that may settle the question. It weighs the promising early signals against the current absence of high-quality human evidence.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Ivermectin

The Grokipedia entry provides a broad, referenced overview of ivermectin’s discovery, approved antiparasitic uses, safety profile, and its more contested proposed uses, offering useful background context on the compound behind the cancer question.

Examine

No Examine.com article exists for ivermectin. Ivermectin is a prescription antiparasitic medication, and Examine.com focuses on dietary supplements and nutrition rather than prescription medications, so no dedicated page was found.

ConsumerLab

No ConsumerLab.com article exists for ivermectin. ConsumerLab tests dietary supplements and consumer health products rather than prescription medications, so no dedicated page was found for this prescription drug.

Systematic Reviews

The following PubMed-indexed review, classified by PubMed as a systematic review, addresses ivermectin’s anticancer activity; no meta-analyses of clinical outcomes exist.

Ivermectin, a Potential Anticancer Drug Derived from an Antiparasitic Drug - Tang et al., 2021

Indexed by PubMed as a systematic review, this paper synthesizes the preclinical mechanisms by which ivermectin inhibits tumor cells across multiple cancer types and promotes programmed cell death. It remains a mechanism-focused synthesis of laboratory work; it does not pool human clinical outcomes, because no controlled clinical trials of efficacy exist to pool.

Mechanism of Action

Ivermectin is a macrocyclic lactone (a large ring-shaped molecule) whose antiparasitic action comes from opening chloride channels unique to invertebrates. Its proposed anticancer effects are separate and multi-target; no single mechanism is established, and the following pathways are drawn largely from laboratory models.

Chloride channels and membrane disruption: In leukemia cells, ivermectin opens chloride channels, causing the cell membrane to lose its normal electrical charge, triggering reactive oxygen species (ROS, unstable oxygen molecules that damage cells) and cell death. This was the first proposed anticancer mechanism identified in blood cancers.
WNT/β-catenin pathway: Ivermectin inhibits WNT/β-catenin signaling (a growth pathway that is overactive in many colon, lung, and other cancers), reducing tumor cell proliferation and promoting apoptosis (programmed cell death).
PAK1 and the Akt/mTOR pathway: In breast cancer cells, ivermectin promotes breakdown of the enzyme PAK1, which in turn dampens the Akt/mTOR pathway (a central cell-growth and survival signal), inducing a self-digesting process called autophagy that halts growth.
Purinergic (P2X4/P2X7) receptors: Ivermectin allosterically strengthens P2X4/P2X7 receptors (cell-surface sensors for the energy molecule ATP), which can trigger tumor cell death and release signals that recruit immune cells — the rationale for combining it with immunotherapy.
Mitochondrial and metabolic stress: It impairs mitochondrial function (the cell’s energy factories) and raises oxidative stress, to which cancer cells with high energy demands may be more vulnerable.
Multidrug-resistance reversal: Ivermectin binds the epidermal growth factor receptor (EGFR, a growth-signal receptor) and lowers P-glycoprotein (P-gp, a pump that expels drugs from cells), which can restore sensitivity to standard chemotherapy in resistant cells.

The central competing interpretation is one of dose. The concentrations that produce these effects in the laboratory are typically about 1–10 micromolar, whereas standard safe human dosing achieves plasma levels roughly 20–200 times lower. Proponents argue tumors may concentrate the drug or that higher/repeated dosing closes the gap; skeptics argue the laboratory effects are simply unreachable at tolerable human doses. Both positions remain unresolved.

Key pharmacological properties: Ivermectin is highly lipophilic (fat-soluble) and about 93% protein-bound, with a plasma half-life commonly cited around 18 hours (some metabolites persist longer). It is metabolized chiefly in the liver by the enzyme CYP3A4 and is a substrate of P-glycoprotein, which actively pumps it out of the brain and limits central nervous system exposure at normal doses. Its target selectivity for invertebrate channels underlies its wide safety margin in humans.

Historical Context & Evolution

Original intended use: Ivermectin was derived in the late 1970s from avermectin, a compound made by the soil bacterium Streptomyces avermitilis discovered by Satoshi Ōmura and developed with William C. Campbell at Merck. It was approved for human use in the 1980s to treat onchocerciasis (river blindness) and strongyloidiasis (a roundworm infection of the gut), and later scabies, head lice, and rosacea. Its impact on parasitic disease earned Ōmura and Campbell the 2015 Nobel Prize in Physiology or Medicine.
Path to cancer research: The first hint of anticancer activity came in 1996, when Didier and colleagues reported that ivermectin could reverse multidrug resistance in tumor cells. Interest expanded after a 2010 study in leukemia cells (published in the journal Blood) described chloride-channel-mediated cell death, and through drug-repurposing screens such as the Repurposing Drugs in Oncology (ReDO) project, which flagged ivermectin as a candidate. The actual findings — reproducible growth inhibition across many cancer cell lines and animal models — are consistent and well documented, even as their human relevance remains unproven.
Evolution of opinion: Scientific opinion has shifted from viewing ivermectin purely as an antiparasitic to regarding it as a plausible repurposing candidate worth testing. That shift accelerated after 2020, when public attention to the drug surged. The current cautious mainstream position — that human efficacy is unproven — is a statement about the present evidence, not a final verdict; it could change as the first randomized trials report. New laboratory evidence continues to accumulate on both the promise (immune-activating effects) and the limits (the dosing gap).

Expected Benefits

The benefits below are framed for a proactive, risk-aware reader weighing an unproven adjunct. It is essential to state plainly that no benefit for treating cancer in humans has been confirmed by controlled clinical trials; the evidence base is overwhelmingly preclinical, and the strongest human signal comes from a single industry-linked observational cohort.

Low 🟩

Broad-Spectrum Suppression of Tumor Cell Growth

Across dozens of laboratory studies, ivermectin slows proliferation and induces cell death in many cancer types, including breast, colorectal, leukemia, glioma, ovarian, and melanoma models, through the pathways described above. Human data are limited to a prospective observational cohort of patients using ivermectin with mebendazole off-label, reported by Hulscher and colleagues; that cohort — funded and operated through The Wellness Company, a telemedicine seller of these drugs, a direct financial conflict of interest — reported high rates of self-reported benefit but has since been the subject of a journal Expression of Concern. The grade is Low because preclinical consistency is strong while human evidence is weak, uncontrolled, and conflicted by commercial interest.

Magnitude: Preclinical half-maximal inhibitory concentrations (IC50, the dose that halves cell growth) typically fall around 1–10 micromolar, with roughly 50–70% tumor-growth inhibition in animal models; the sole human cohort reported self-reported regression or no evidence of disease in about 48% of participants, an unverified and uncontrolled figure.

Speculative 🟨

Enhancement of Cancer Immunotherapy

Laboratory work suggests ivermectin can trigger a form of tumor cell death that alerts the immune system and increases infiltration of cancer-fighting T-cells, which could make immunotherapy drugs (checkpoint inhibitors) work better. This is the most actively pursued clinical hypothesis, with early-phase trials underway, but no human results yet exist; the basis is mechanistic and preclinical only.

Reversal of Chemotherapy Resistance

By lowering the P-glycoprotein pump and blocking EGFR signaling, ivermectin restored sensitivity to standard chemotherapy in drug-resistant cancer cells and animal models. The basis is entirely preclinical; whether this translates to patients who have stopped responding to chemotherapy is untested.

Activity Against Cancer Stem Cells

Some studies indicate ivermectin preferentially targets cancer stem-like cells — a small population thought to drive relapse — and can suppress the epithelial-to-mesenchymal transition (EMT, a cell change linked to spread). This is a mechanistically appealing but wholly unproven benefit resting on cell-line and animal data.

Benefit-Modifying Factors

Drug-transport genetics (ABCB1/MDR1): The ABCB1 gene (also called MDR1) encodes P-glycoprotein, the pump that expels ivermectin from cells. Reduced-function variants may raise intracellular and tumor drug levels, potentially increasing any anticancer effect — but the same variants raise toxicity risk.
Metabolism genetics (CYP3A4/5): Variants in the CYP3A4 and CYP3A5 liver enzymes that clear ivermectin can raise or lower blood levels, plausibly shifting both benefit and risk, though this has not been studied in a cancer context.
Tumor pathway status: Benefits, if real, are likely greatest in tumors driven by the pathways ivermectin targets — for example cancers with an overactive WNT/β-catenin pathway or high P2X4 receptor expression. Baseline molecular profiling of the tumor is the relevant “biomarker.”
Baseline liver function: Because the drug is liver-metabolized, baseline liver health influences exposure and therefore any dose-dependent benefit.
Sex differences: No reliable sex-based differences in anticancer response have been established; antiparasitic pharmacokinetics are broadly similar between sexes, and cancer-specific data are absent.
Age: Older adults at the upper end of the target range may have slower drug clearance and more comorbidity, which could alter the benefit-risk balance, though no age-stratified efficacy data exist for cancer.

Potential Risks & Side Effects

Risks are framed for a proactive reader who may consider off-label use. At standard antiparasitic doses ivermectin is well tolerated; the concern in the cancer setting is the high, prolonged, off-label dosing that repurposing advocates promote, often sourced outside medical supervision. A dedicated search of drug-reference and clinical sources informed this section.

High 🟥 🟥 🟥

Central Nervous System Neurotoxicity

The most serious risk is neurological. At high doses — or when the blood-brain barrier is compromised (for example by brain metastases) or P-glycoprotein is inhibited — ivermectin can enter the brain and cause confusion, tremor, ataxia (loss of muscle coordination), seizures, coma, and respiratory failure. A 2026 case report described a woman with metastatic breast cancer who developed seizures and respiratory failure requiring intensive care after high-dose self-administration. The mechanism is excessive activation of inhibitory chloride channels in the central nervous system.

Magnitude: Serious neurotoxicity is rare at approved doses (well under 1%) but documented in overdose and high-dose self-treatment, with published cases requiring intubation and intensive care; risk rises sharply with brain involvement or interacting drugs.

Medium 🟥 🟥

Gastrointestinal Adverse Effects

Nausea, diarrhea, abdominal pain, and loss of appetite are the most common complaints and are dose-dependent, becoming more frequent at the elevated doses used for cancer than at antiparasitic doses. The likely mechanism is direct irritation of the gastrointestinal lining combined with the drug’s effect on gut motility, often compounded by the fatty meals taken to boost absorption. The evidence base is drawn from prescribing information, decades of antiparasitic clinical experience, and the off-label cancer cohort, where these effects were the predominant reported adverse events. They are generally mild and manageable with dose adjustment.

Magnitude: Reported by roughly a quarter of users in the off-label cohort, predominantly mild and manageable with dose adjustment; most users continued therapy.

Hepatotoxicity

Ivermectin can raise liver enzymes, and rare cases of clinically significant liver inflammation (hepatitis) have been reported. Because it is cleared by the liver, sustained high dosing plausibly increases this risk, and pre-existing liver disease compounds it.

Magnitude: Usually reversible enzyme elevations; clinically significant liver injury is uncommon but reported, warranting monitoring during prolonged use.

Substitution for Evidence-Based Cancer Therapy

A distinct and serious harm is behavioral: patients who use ivermectin in place of proven treatment may forgo therapies with established survival benefit. Oncology commentators identify this “opportunity cost” as the dominant real-world danger, amplified by online misinformation.

Magnitude: Not quantified in available studies.

Low 🟥

Ocular and Visual Disturbances

Blurred vision and other transient visual disturbances have been reported, mainly at higher doses. The proposed mechanism is a mild central nervous system effect on visual processing, linked to the same chloride-channel activity that drives neurotoxicity at high exposure. The evidence comes from antiparasitic prescribing information and post-marketing reports rather than controlled cancer studies. These disturbances are generally reversible, resolving with dose reduction or discontinuation.

Magnitude: Rare and typically reversible; more likely with high cumulative dosing.

Speculative 🟨

Unknown Long-Term Safety at Anticancer Doses

The safety of taking ivermectin at high doses continuously for months to years — as some cancer protocols suggest — has never been formally studied. Cumulative or delayed harms cannot be excluded; the basis for concern is the absence of data rather than reported cases.

Risk-Modifying Factors

Blood-brain barrier integrity: Anything that weakens the blood-brain barrier — brain metastases, meningeal disease, or inflammation — sharply increases the risk of neurotoxicity by allowing the drug into the brain. This is the single most important risk modifier in cancer patients.
Drug-transport genetics (ABCB1/MDR1): Loss-of-function variants in the ABCB1 gene reduce the P-glycoprotein pump that keeps ivermectin out of the brain, raising neurotoxicity risk; this is the human parallel to the well-known ivermectin toxicity in certain herding-dog breeds with an MDR1 mutation.
CYP3A4-affecting comedications and status: Drugs, foods, or genetic variants that slow CYP3A4 metabolism raise blood levels and toxicity risk; those that speed it lower drug exposure.
Hepatic function: Impaired liver function reduces clearance, increasing exposure and the risk of both liver and nervous-system toxicity.
Sex differences: No consistent sex-based differences in the risk or severity of adverse effects have been established for ivermectin.
Age: Older adults may clear the drug more slowly and are more likely to take interacting medications, modestly increasing risk at the upper end of the target range.

Key Interactions & Contraindications

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin): Caution — these raise ivermectin blood levels and can precipitate neurotoxicity. Mitigation: avoid the combination or reduce dose and monitor for neurological symptoms.
P-glycoprotein inhibitors (verapamil, quinidine, cyclosporine, ritonavir): Caution — inhibiting the pump increases brain penetration and neurotoxicity risk. Mitigation: avoid concurrent use; if unavoidable, monitor closely.
Central nervous system depressants and GABA-active drugs (drugs acting on GABA, the brain’s main calming chemical messenger; benzodiazepines, barbiturates, valproate, alcohol): Caution — potential additive sedation and heightened neurotoxicity. Mitigation: separate use and avoid alcohol.
Warfarin (a blood thinner): Monitor — isolated reports of increased anticoagulant effect. Mitigation: check clotting values (INR) more frequently if combined.
Over-the-counter agents: Few significant interactions; alcohol and sedating antihistamines may add to central nervous system effects. Mitigation: minimize during dosing.
Supplements and foods: Grapefruit juice inhibits CYP3A4 and can raise levels (avoid); St. John’s Wort induces CYP3A4 and can lower levels (reduces any effect); high-fat meals substantially increase absorption. Mitigation: keep intake of these consistent and disclose them.
Additive/combination agents: Ivermectin is frequently stacked with other repurposed antiparasitics (mebendazole, fenbendazole) and with immunotherapy in trials; combined regimens increase both theoretical benefit and the chance of overlapping toxicity, and should only be undertaken with oversight.
Populations who should avoid or use extreme caution: Pregnancy and breastfeeding; children under roughly 15 kg; significant hepatic impairment (Child-Pugh Class B or C); active central nervous system involvement such as brain metastases or leptomeningeal disease (cancer spread to the membranes covering the brain and spinal cord); a history of Loa loa infection (a parasitic worm; encephalopathy, or brain inflammation, risk); and known hypersensitivity.

Risk Mitigation Strategies

Use only as an adjunct under medical supervision, never as a replacement: The single most important safeguard against the dominant harm — forgoing proven therapy — is to keep evidence-based cancer treatment in place and treat ivermectin, if used at all, as an experimental add-on within a trial or physician-guided plan.
Screen for central nervous system involvement before use: Because brain metastases and a leaky blood-brain barrier drive neurotoxicity, imaging status should be known; those with active brain disease should avoid high-dose use to prevent seizures and coma.
Start low and titrate slowly: Beginning well below advocate-promoted doses and increasing gradually limits dose-dependent gastrointestinal, hepatic, and neurological toxicity.
Avoid CYP3A4 and P-glycoprotein inhibitors, including grapefruit: Eliminating these interacting drugs and foods prevents the drug-level spikes that cause neurotoxicity; medication reconciliation before starting is the practical step.
Monitor liver enzymes and neurological symptoms: Checking liver function (for example every 4–8 weeks during sustained use) and stopping promptly for confusion, tremor, or visual change mitigates hepatotoxicity and serious neurotoxicity.
Use pharmaceutical-grade human formulations only: Avoiding veterinary “horse paste” and unregulated products prevents accidental overdose and excipient-related harm from imprecise, concentrated dosing.

Therapeutic Protocol

There is no validated anticancer protocol for ivermectin; the following contrasts the two main real-world approaches without endorsing either.

Conventional oncology position: Leading cancer bodies and the U.S. Food and Drug Administration (FDA, the U.S. drug regulator) advise that ivermectin should not be used for cancer outside a clinical trial, because human efficacy is unproven and harms are documented. Under this view there is no dose or schedule to recommend.
Integrative/repurposing protocols: A separate community of physician-advocates — notably the Front Line COVID-19 Critical Care Alliance (FLCCC) and clinicians such as Paul Marik and Peter McCullough, who popularized these regimens — publishes off-label protocols. These typically use oral ivermectin around 0.5–1 mg/kg daily, frequently combined with mebendazole (and sometimes fenbendazole), vitamin D, and dietary changes. These protocols are experience-based and not validated by controlled trials, and they carry the advocacy and, in some cases, commercial interests of their proponents.
Best time of day and food: Because a fatty meal roughly doubles absorption, timing relative to food materially affects exposure; advocate protocols generally direct dosing with food, and consistency matters more than a specific hour.
Half-life and dosing frequency: With a plasma half-life near 18 hours, once-daily dosing is typical; some protocols split doses to reduce peak-related side effects.
Genetic factors: ABCB1/MDR1 status affects both brain exposure and tumor uptake and could in principle guide caution or dose, though no protocol formally incorporates genotyping.
Sex-based differences: No sex-specific dosing is established for the anticancer setting.
Age considerations: Older adults at the upper end of the target range may warrant lower starting doses and closer monitoring due to slower clearance and comorbidity.
Baseline biomarkers: Baseline liver function and, where feasible, tumor molecular profiling are the relevant inputs proponents use to gauge suitability.
Pre-existing conditions: Liver disease, seizure history, and central nervous system disease all argue for avoidance or extreme caution.

Discontinuation & Cycling

Lifelong vs. short-term: Whether any anticancer use should be short-term or prolonged is unknown; advocate protocols often continue for months, but no evidence defines an optimal duration.
Withdrawal effects: Ivermectin causes no known physical dependence or withdrawal syndrome, and it can be stopped without tapering from a safety standpoint.
Tapering: No tapering protocol is required for discontinuation; dose reduction is used only to manage side effects during ongoing use.
Cycling: Some integrative protocols pulse or cycle dosing to limit cumulative toxicity, but there is no efficacy evidence that cycling maintains or improves any anticancer effect.

Sourcing and Quality

Pharmaceutical-grade human product: The appropriate form is prescription human ivermectin (for example 3 mg tablets), which offers accurate, consistent dosing; veterinary pastes and unregulated online products should be avoided because concentration and excipients are not designed for precise human dosing.
Compounding pharmacies: Higher off-label doses are sometimes supplied as compounded capsules; a reputable, licensed compounding pharmacy with quality controls is preferable to unverified sellers, though compounded products still lack the oversight of approved tablets.
What to look for: Verified potency and purity, clear labeling of milligram strength, and sourcing from a licensed pharmacy rather than agricultural or gray-market suppliers.
Telemedicine channels: Some telehealth services prescribe and ship ivermectin for off-label use; buyers should recognize that several such services have direct financial interests in promoting the drug, which can bias the information provided.

Practical Considerations

Time to effect: There is no established time to benefit because efficacy is unproven; the observational cohort assessed outcomes at six months, but no reliable timeframe for any anticancer effect exists.
Common pitfalls: Using veterinary formulations, overdosing in pursuit of laboratory-level concentrations, abandoning proven treatment, combining with interacting drugs, and expecting rapid tumor response are the most frequent and dangerous mistakes.
Regulatory status: Ivermectin is FDA-approved as an antiparasitic but not for cancer; cancer use is off-label, and the FDA has explicitly warned against using it to treat cancer outside clinical trials.
Cost and accessibility: The drug is inexpensive and globally available, which is precisely why it attracts repurposing interest and why commercial developers have little incentive to fund the large trials needed to prove or disprove benefit. Institutional payers (insurers and national health systems) would stand to save substantially if a cheap generic displaced costly oncology drugs, yet because no manufacturer can recoup the cost of pivotal trials on an off-patent compound, neither industry nor payers reliably finance them — a structural funding bias that keeps the human evidence base thin and largely absent from treatment guidelines.

Interaction with Foundational Habits

Sleep: Indirect/none — ivermectin has no established effect on sleep at normal doses, though high doses causing central nervous system effects could disrupt it. Practical point: report any new confusion or sedation, which can affect sleep and signals toxicity.
Nutrition: Direct/potentiating — a high-fat meal roughly doubles absorption, so food timing meaningfully changes drug exposure; some metabolic protocols pair the drug with low-carbohydrate or fasting approaches on the theory of added metabolic stress on tumors, though this synergy is unproven. Practical point: keep fat intake around dosing consistent to avoid unpredictable levels.
Exercise: None known — there is no established interaction between ivermectin and exercise or muscle adaptation. Practical point: no timing adjustment around workouts is indicated.
Stress management: None known — ivermectin is not known to affect cortisol or the stress response directly. Practical point: standard stress-reduction practices remain relevant to overall cancer care but do not interact pharmacologically with the drug.

Monitoring Protocol & Defining Success

Before starting off-label ivermectin, a baseline assessment establishes liver and blood status and a neurological reference point, so that emerging toxicity can be detected early. Ongoing monitoring should occur at roughly 4-week intervals during the first few months, then every 3–6 months if continued, with prompt testing for any new symptoms.

Baseline labs and a neurological exam should be completed before the first dose; ongoing labs follow the cadence above.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT	10–26 U/L	Detects drug-related liver stress early	ALT (alanine aminotransferase) is a liver enzyme; functional target is tighter than the conventional upper limit (~40–55 U/L); fasting not required
AST	10–26 U/L	Complements ALT for liver injury	AST (aspartate aminotransferase) is a liver enzyme; can also rise with muscle stress; interpret alongside ALT
Total bilirubin (a liver waste product)	0.3–1.0 mg/dL	Flags impaired liver clearance	Conventional range extends to ~1.2 mg/dL; best measured fasting in the morning
Complete blood count	Within lab reference range	Baseline for overlapping cancer/therapy effects	Distinguishes drug effects from disease or chemotherapy
Creatinine (a kidney marker)	0.6–1.1 mg/dL	Baseline organ function before sustained dosing	Pair with liver panel; hydration affects values

Qualitative markers:
- Neurological status: alertness, coordination, absence of tremor or confusion (the key safety signal)
- Vision: any new blurring or visual change
- Energy and appetite: general tolerance and gastrointestinal comfort
- Overall well-being and, where measured by the oncology team, objective tumor response on imaging

Emerging Research

The most meaningful evidence gap — controlled human data — is beginning to be addressed by early-phase trials, most testing ivermectin as a partner for immunotherapy rather than as a solo treatment.

Ivermectin plus immunotherapy in triple-negative breast cancer: A Phase 1/2 trial (NCT05318469) is recruiting patients with metastatic triple-negative breast cancer (TNBC, an aggressive subtype) to test oral ivermectin combined with the checkpoint-inhibitor immunotherapies balstilimab or pembrolizumab, with objective response rate and safety as primary endpoints (about 34 participants).
Ivermectin plus checkpoint inhibition (ICONIC): A Phase 2 trial (NCT07487805) led by the University of Florida is planned in adults with solid tumors, using an immune biomarker — the change in activated CD8 T-cells (CD8 T-cells are the immune system’s cancer-killing cells) — as its primary endpoint to test whether ivermectin measurably boosts anti-tumor immunity (about 80 participants).
Real-world observational signal: A prospective observational cohort (PMID 42203321) of patients using ivermectin with mebendazole reported high self-reported benefit, but it was operated through a commercial telemedicine seller of the drugs — a direct financial conflict of interest — and is the subject of a journal Expression of Concern; it is hypothesis-generating at best.
Preclinical combinations to watch: Studies report synergy between ivermectin and metformin in breast cancer models (Feng et al., 2025) and activity against endocrine-resistant breast cancer via WNT signaling (Rujimongkon et al., 2025); these could strengthen the rationale for specific human trials.
What could change the picture: Positive randomized results in the immunotherapy-combination trials would strengthen the case, whereas failure to show benefit, or accumulating neurotoxicity reports from off-label use, would weaken it. The unresolved question of whether tolerable human doses reach active tumor concentrations remains central and could be settled by pharmacokinetic studies embedded in these trials.

Conclusion

Ivermectin is a cheap, long-established antiparasitic drug that laboratory research suggests can slow many kinds of cancer cells through several distinct actions, including disrupting cell signaling and energy production and stirring the immune system. For a reader looking to act on the best evidence, the honest summary is that this promise remains almost entirely unproven in people. No controlled human trial has yet shown that it treats cancer, and the one real-world study suggesting benefit was run by a company that sells the drug and has been formally questioned by its journal.

Against uncertain benefit sit real risks: serious nervous-system harm at high or self-administered doses, liver and stomach effects, and — most importantly — the danger of using it instead of treatments known to work. The strongest current direction is testing it alongside standard immunotherapy, where early trials are just beginning.

The evidence base is lopsided: rich in laboratory findings, thin in human proof, and shaped by advocates on one side and little commercial interest to fund rigorous trials on the other. Until those trials report, ivermectin for cancer is best understood as a scientifically interesting, actively studied, but currently unverified possibility.

Top - Benefits - Risks - Protocol

Ivermectin to Treat Cancer

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

Low 🟩

Broad-Spectrum Suppression of Tumor Cell Growth

Speculative 🟨

Enhancement of Cancer Immunotherapy

Reversal of Chemotherapy Resistance

Activity Against Cancer Stem Cells

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Central Nervous System Neurotoxicity

Medium 🟥 🟥

Gastrointestinal Adverse Effects

Hepatotoxicity

Substitution for Evidence-Based Cancer Therapy

Low 🟥

Ocular and Visual Disturbances

Speculative 🟨

Unknown Long-Term Safety at Anticancer Doses

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion